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Conclusions: Use of MIM software failed to improve the conformity 
level and showed no significant time-saving in this study. Further 
research and demonstrable benefits are required before it can be 
incorporated into routine practice for prostate cancer outlining. 
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Purpose/Objective: Accurate and reproducible patient (pts) 
positioning during radiotherapy is necessary for precise dose delivery. 
The aim of the study was to evaluate target positioning accuracy 
during prostate cancer (PC) treatment using cone beam CT (CBCT) 
image-guided localization system (XVI, Elekta) during a few fractions 
(fr) of radiotherapy. 
Materials and Methods: 22 pts with PC were treated in supine position 
on linear accelerator (Elekta Synergy) equipped with XVI (v.4.2). CBCT 
was performed according to our protocol on 1,2,3,4,11, 21 and 29 day 
of treatment. The results of matching the reference planning CT scans 
with CBCT datasets were represented as translations and rotations in 
3 directions: lateral (X), longitudinal (Y) and vertical (Z). However, 
the table on accelerator allowed correcting translations only. 
Results: The translations variations (cm) for the first three fractions 
were: on 1st fr:-0.06±0.25; 0.19±0.44; -0.11±0.33 in X,Y,Z direction, 
respectively. On the 2nd fr: -0.01±0.27; 0.16±0.47; -0.23±0.33 and on 
the 3rd fr: -0.09±0.34;0.14±0.38; -0.19±0.32 along X, Y and Z 
directions, respectively. The 3D vector was 0.53±0.36; 0.59±0.34; 
0.60±0.24 for the 1,2,3 fr respectively. On the 4 fr, after the 
calculation the mean of translations from the 1,2,3 fr, the X,Y,Zshifts 
were as follows: 0.9±0.29; 0.01±0.3; -0.09±0.24 with the vector length 
of 0.44±0.2. During the succeeding fr the following shifts in X, Y, Z 
direction were evaluated: on the 11th fr 0.05±0.33; 0.00±0.3; 
0.04±0.27; on the 21st fr-0.02±0.29; 0.09±0.37; -0.03±0.17 and on the 
29th fr -0.13±0.41; 0.07±0.29;0.10±0.27. The magnitude of 3D vector 
was 0.45±0.23; 0.45±0.22; 0.50±0.21 for the 11,21,29 fr, respectively. 
Conclusions: Our protocol seems to be a useful tool for overloaded 
radiotherapy departments, where performing every day CT-based 
IGRT is impossible. The greatest discrepancy between target position 
on reference planning CT and pretreatment CBCT on the accelerator 
was observed during the first fractions and decreased in the 
succeeding fr. The CBCT is a useful tool in determining and improving 
the accuracy of radiotherapy in PC. 
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Purpose/Objective: New technologies such as intensity modulated 
and image guided radiation therapy have been shown to decrease 
acute toxicity for prostate cancer (PC). We present the clinical results 
and the assessment of prognostic factors of radiation therapy with 
helical tomotherapy (HT) for clinically localized and recurrent PC, as 
well as post-prostatectomy adjuvant treatment. 
Materials and Methods: From May 2006 to January 2011, 70 cT1-T3 
cN0 cM0 PC patients were treated with HT (primary diagnosis, n=48; 
post-prostatectomy biochemical recurrence, n=15; post-brachytherapy 
biochemical recurrence, n=2; and post-prostatectomy adjuvance, 
n=5). The dose prescribed to the prostate ranged between 72-78Gy, 
except for one case (post-brachytherapy recurrence, 66Gy) with 
conventional fractionation (2Gy/fraction). The seminal vesicles 
received between 50-56Gy, the surgical bed 66-74Gy, and the pelvic 
lymph nodes 46-50.4Gy (n=20), respectively when applicable, with 
conventional fractionation. Genitourinary (GU) and gastrointestinal 
(GI) toxicity was scored using the Radiation Therapy Oncology Group 
(RTOG) scoring system. Potential risk factors for toxicity were 
assessed in univariate and multivariate logistic regression analysis. 
Results: The median age was 68 years (range 51-87 years). The 
median follow-up was 37 months (range 3-74 months). The mean 
initial Gleason score was 6 and the mean initial PSA was 17 ng/ml. For 
patients with a primary diagnosis or those receiving adjuvant HT, 
median overall survival was 45 months (range, 8-82 months). For 
patients receiving HT for biochemical recurrence, overall survival was 
24 months (range, 3-73 months). Overall, only 3 patients died, and 
none of them due to a cancer-related cause. Local recurrence was 
seen in 1 patient which had been treated for a biochemical recurrence 
after initial prostatectomy. Regional recurrence and bone disease only 
occurred in one patient with primary intermediate risk PC. The rates 
of acute grade 2 gastrointestinal (GI) and genitourinary (GU) toxicities 
were 13% and 10 %, respectively. Only one patient experienced acute 
grade 3 GU toxicity. The rates of late grade 2 GI toxicities were 1.5%, 
and those of late grade 2 GU toxicities were 1.2 %. No patients 
experienced late Grade ≥3 toxicity. Multivariate analysis showed that 
receiving a rectum mean dose >median (39 Gy) or a bladder median 
dose >median (46 Gy) was associated with a higher grade of acute GI 
(OR: 3.53; P =0.017) and GU toxicity, respectively (OR: 5.31; P 
=0.019). In addition, having an older age was associated with a higher 
grade of late GU toxicity (OR: 3.94; P =0.026). 
Conclusions: This preliminary report confirms the feasibility of HT for 
prostate cancer. HT is associated with a very low risk of toxicity and a 
low recurrence rate. Acute and late gastrointestinal and genitourinary 
toxicities were tolerable without any grade > 3 side effects.  
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Purpose/Objective: The aim of the present study was to evaluate the 
prevalence and severity of lower limb lymphedema after pelvic 
lymphadenectomy and radiotherapy to the pelvic lymph nodes in 
patients with prostate cancer. 
Materials and Methods: Twenty-six patients underwent combined 
treatment for high-risk node positive prostate cancer at the 
department of oncology at Skåne University Hospital between April 
2008 and March 2011. The treatment consisted of pelvic 
lymphadenectomy followed by androgen deprivation therapy and 
radiotherapy to the pelvic lymph nodes and prostate. The pelvic 
nodes, prostate and seminal vesicles were treated with external beam 
radiotherapy (EBRT) to an absorbed dose of 50 Gy followed by a 
brachytherapy boost of 2*10 Gy to the prostate only. Twenty-two 
patients accepted an invitation to a clinical examination with focus on 
lower limb swelling. The time between RT and examination was 
median 2.4 years (range 1.2-4.1 y). 
Results: Six patients (27%) experienced grade 1 lymphedema and two 
patients (9%) grade 2 while none had grade 3 or 4 according to the 
CTC Common Toxicity Criteria scale 4.0. Three patients required 
treatment with compression socks. 
Conclusions: Brachytherapy and pelvic EBRT have a low incidence of 
lymphedema in patients with high risk node positive prostate cancer 
that have undergone pelvic lymph node dissection. The follow-up time 






   
